Julia Warner Gargano1, Ina U Park2, Marie R Griffin3, Linda M Niccolai4, Melissa Powell5, Nancy M Bennett6, Michelle L Johnson Jones1, Erin Whitney7, Manideepthi Pemmaraju3, Monica Brackney4, Nasreen Abdullah5, Mary Scahill6, Rebecca M Dahl8, Angela A Cleveland1, Elizabeth R Unger9, Lauri E Markowitz1. 1. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. 2. Department of Family and Community Medicine, School of Medicine, University of California at San Francisco. 3. Vanderbilt University Medical Center, Nashville, Tennessee. 4. Yale School of Public Health, New Haven, Connecticut. 5. Oregon Health Authority Public Health Division, Portland. 6. University of Rochester School of Medicine and Dentistry, New York. 7. California Emerging Infections Program, Richmond. 8. MAXIMUS Federal, contracting agency to National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia. 9. National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, Georgia.
Abstract
BACKGROUND: We describe changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ (CIN2+) during a period of human papillomavirus (HPV) vaccine uptake and changing cervical cancer screening recommendations. METHODS: We conducted population-based laboratory surveillance for CIN2+ in catchment areas in 5 states, 2008-2015. We calculated age-specific CIN2+ rates per 100000 women by age groups. We estimated incidence rate ratios (IRR) of CIN2+ for 2-year periods among all women and among screened women to evaluate changes over time. RESULTS: A total of 16572 CIN2+ cases were reported. Among women aged 18-20 and 21-24 years, CIN2+ rates declined in all sites, whereas in women aged 25-29, 30-34, and 35-39 years, trends differed across sites. The percent of women screened annually declined in all sites and age groups. Compared to 2008-2009, rates among screened women were significantly lower for all 3 periods in women aged 18-20 years (2010-2011: IRR 0.82, 95% confidence interval [CI] 0.67-0.99; 2012-2013: IRR 0.63, 95% CI 0.47-0.85; 2014-2015: IRR 0.44, 95% CI 0.28-0.68) and lower for the latter 2 time periods in women aged 21-24 years (2012-2013: IRR 0.86, 95% CI 0.79-0.94; 2014-2015: IRR 0.61, 95% CI 0.55-0.67). CONCLUSIONS: From 2008-2015, both CIN2+ rates and cervical cancer screening declined in women aged 18-24 years. The significant decreases in CIN2+ rates among screened women aged 18-24 years are consistent with a population-level impact of HPV vaccination. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
BACKGROUND: We describe changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ (CIN2+) during a period of human papillomavirus (HPV) vaccine uptake and changing cervical cancer screening recommendations. METHODS: We conducted population-based laboratory surveillance for CIN2+ in catchment areas in 5 states, 2008-2015. We calculated age-specific CIN2+ rates per 100000 women by age groups. We estimated incidence rate ratios (IRR) of CIN2+ for 2-year periods among all women and among screened women to evaluate changes over time. RESULTS: A total of 16572 CIN2+ cases were reported. Among women aged 18-20 and 21-24 years, CIN2+ rates declined in all sites, whereas in women aged 25-29, 30-34, and 35-39 years, trends differed across sites. The percent of women screened annually declined in all sites and age groups. Compared to 2008-2009, rates among screened women were significantly lower for all 3 periods in women aged 18-20 years (2010-2011: IRR 0.82, 95% confidence interval [CI] 0.67-0.99; 2012-2013: IRR 0.63, 95% CI 0.47-0.85; 2014-2015: IRR 0.44, 95% CI 0.28-0.68) and lower for the latter 2 time periods in women aged 21-24 years (2012-2013: IRR 0.86, 95% CI 0.79-0.94; 2014-2015: IRR 0.61, 95% CI 0.55-0.67). CONCLUSIONS: From 2008-2015, both CIN2+ rates and cervical cancer screening declined in women aged 18-24 years. The significant decreases in CIN2+ rates among screened women aged 18-24 years are consistent with a population-level impact of HPV vaccination. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
Entities:
Keywords:
cervical intraepithelial neoplasia; disease surveillance; human papillomavirus; vaccine impact
Authors: Warner K Huh; Kevin A Ault; David Chelmow; Diane D Davey; Robert A Goulart; Francisco A Garcia; Walter K Kinney; L Stewart Massad; Edward J Mayeaux; Debbie Saslow; Mark Schiffman; Nicolas Wentzensen; Herschel W Lawson; Mark H Einstein Journal: J Low Genit Tract Dis Date: 2015-04 Impact factor: 1.925
Authors: Susan Hariri; Michelle L Johnson; Nancy M Bennett; Heidi M Bauer; Ina U Park; Sean Schafer; Linda M Niccolai; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Date: 2015-06-22 Impact factor: 6.860
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Harrell W Chesson; C Robinette Curtis; Julianne Gee; Joseph A Bocchini; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2014-08-29
Authors: Meg Watson; Ashwini Soman; Elaine W Flagg; Elizabeth Unger; Dennis Deapen; Vivien W Chen; Lauren C Peres; Glenn Copeland; Thomas C Tucker; Erin Garnett; Mona Saraiya Journal: Prev Med Date: 2017-07-29 Impact factor: 4.018
Authors: Nancy M McClung; Julia W Gargano; Nancy M Bennett; Linda M Niccolai; Nasreen Abdullah; Marie R Griffin; Ina U Park; Angela A Cleveland; Troy D Querec; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-21 Impact factor: 4.254
Authors: Jaimie Z Shing; Marie R Griffin; Rachel S Chang; Alicia Beeghly-Fadiel; Staci L Sudenga; James C Slaughter; Manideepthi Pemmaraju; Edward F Mitchel; Pamela C Hull Journal: Am J Prev Med Date: 2021-10-29 Impact factor: 5.043
Authors: Monica M Brackney; Daniel M Weinberger; Kyle Higgins; James Meek; Linda M Niccolai Journal: Public Health Rep Date: 2021-11-02 Impact factor: 3.117
Authors: Rayleen M Lewis; Allison L Naleway; Nicola P Klein; Bradley Crane; Amber Hsiao; Laurie Aukes; Julius Timbol; Troy D Querec; Martin Steinau; Sheila Weinmann; Elizabeth R Unger; Lauri E Markowitz Journal: J Low Genit Tract Dis Date: 2022-04-01 Impact factor: 3.842
Authors: Angela A Cleveland; Julia W Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Kayla Saadeh; Manideepthi Pemmaraju; Kyle Higgins; Sara Ehlers; Mary Scahill; Michelle L Johnson Jones; Troy Querec; Lauri E Markowitz; Elizabeth R Unger Journal: Int J Cancer Date: 2019-05-06 Impact factor: 7.316
Authors: Jacqueline M Mix; Elizabeth A Van Dyne; Mona Saraiya; Benjamin D Hallowell; Cheryll C Thomas Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-20 Impact factor: 4.090